Methicillin-resistant Staphylococcus aureus (MRSA) was first detected in 1961 (1) . Its incidence has continued to increase, especially in the 1980s (2, 8, 9) . Since MRSA resists not only methicillin, but also cephems, aminoglycosides, tetracyclines, macrolides, and new quinolones (2, 3, 6, 8, 9) , its increase and prevalence pose serious clinical and epidemiological problems all over the world. Therefore, it is necessary to find a new type of drug with anti-MRSA activity.
Selenium is an essential trace element for mammals, since it is contained in glutathione (GSH) peroxidase, which catalyzes the reduction of a variety of hydroperoxides and undergoes a catalytic redox cycle between the selenol and selenenic and/or seleninic acids (11) . The seleno-organic compound 2-phenyl-1,2-benzoisoselenazol-3(2H)-one (PZ51; Fig. 1 ), exhibits GSH peroxidase-like activity in vitro, in contrast to its sulfur analog, PZ25 (5, 7, 10) . In addition, PZ51 had an antioxidant activity in microsomal lipid peroxidation even in the absence of GSH (5), offering a novel type of anti-inflammatory agent with low toxicity (10). We studied the antibacterial spectrum of PZ51 and found that some gram-positive cocci were more susceptible to PZ51 than some gram-negative species. We then examined the susceptibility of clinically isolated MRSA strains to PZ51.
PZ51 and PZ25 were solubilized in dimethyl sulfoxide to 10 mg/ml, and heart infusion agar plates containing twofold serially decreasing concentrations of the drug (100 to 0.1 pLg/ml) were made. Each bacterial strain was cultured overnight in NZY broth (5 g of NaCl, 2 g of MgSO4 7H20, 5 g of yeast extract, and 10 g of casein hydrolysate per liter [pH 7.5]), and the broth was diluted 100-fold in saline G (4 Furthermore, susceptibility of clinically isolated coagulasenegative staphylococci (n = 33) and Enterococc usfaiecalis (n = 39) to PZ51 was determined. The MIC for 90% of the strains of either bacterium was 0.78 jg/ml. Since PZ25, a sulfur analog of PZ51 ( Fig. 1) , had little anti-MRSA activity, it was suggested that selenium is essential for the antibacterial activity of PZ51. PZ25 also lost its GSH peroxidase-like activity and its antioxidant activity against microsomal peroxides in the absence of GSH, while PZ51 retained both activities (5, 7, 10) . Thus, the antioxidant activities of PZ51 are apparently correlated with its antibacterial activity. Studies using structural analogs of PZ51 other than PZ25 could clarify the above correlation. Also, studies on the bactericidal activities of other compounds with antioxidant activity could be helpful. The fact that PZ51 was not very effective on gram-negative strains or on streptococcal species (Table 1) might offer a clue to the antibacterial mechanism of the drug. There is now a strong demand for the development of a drug with anti-MRSA activity, and studies on the antimicrobial mechanism of PZ51 could be useful for that development.
